Willemijn T.
- Country
- The Netherlands
- Department
- pulmonary oncology
Research Overview
- Phase 2 Open‑Label Multicohort Study of Rinatabart Sesutecan Monotherapy in Patients with Locally Advanced or Metastatic Non‑Small Cell Lung Cancer
- Three‑Cycle Cemiplimab Immunotherapy Versus Standard Radiotherapy for Recurrence‑Free Survival in Medically Inoperable Stage I Non‑Small Cell Lung Cancer
- Anti-PD-1 re-challenge after immune priming by ipilimumab and immune boosting by radiotherapy in advanced NSCLC.
Data & Insights
Has run more than one trial at 169 of 370 partner sites.
Specializations
Thoracic Oncology
Clinical research activity is centered on non-small cell lung cancer, small cell lung cancer, and other advanced thoracic malignancies, with strong involvement in biomarker-driven treatment strategies and immunotherapy-based combinations.
- Non-small cell lung cancer
- Small cell lung cancer
- EGFR-mutated and ALK-rearranged lung cancer
- ROS1-positive and KRAS G12C-mutant lung cancer
- Pleural mesothelioma
Therapeutic interests include immune checkpoint inhibition, targeted therapy for oncogenic drivers, and treatment approaches for locally advanced and metastatic disease.
Gastrointestinal and Hepatopancreatobiliary Cancers
The investigator is engaged in studies across colorectal cancer, gastric cancer, esophageal cancer, pancreatic cancer, and biliary tract cancer, including molecularly selected advanced solid tumors.
- Colorectal cancer
- Gastric and gastroesophageal junction adenocarcinoma
- Esophageal squamous cell carcinoma
- Pancreatic ductal adenocarcinoma
- Biliary tract cancer
Key domains include perioperative therapy, neoadjuvant treatment, and biomarker-defined immunotherapy for mismatch repair–deficient and KRAS-altered malignancies.
Genitourinary and Gynecologic Oncology
Research spans urothelial carcinoma, renal cell carcinoma, prostate cancer, and a broad range of gynecologic cancers, including cervical, ovarian, endometrial, vulvar, and vaginal malignancies.
- Urothelial carcinoma
- Renal cell carcinoma
- Prostate cancer
- Cervical cancer
- Ovarian and endometrial cancer
Therapeutic focus includes immunotherapy, combined modality treatment, and organ-preserving strategies in selected tumors.
Melanoma, Skin, and Rare Solid Tumors
The clinical portfolio also includes melanoma, cutaneous squamous cell carcinoma, basal cell carcinoma, sarcoma, and other uncommon advanced solid tumors requiring specialized systemic treatment.
- Melanoma
- Cutaneous squamous cell carcinoma
- Soft tissue sarcoma
- Gastrointestinal stromal tumor
- Neuroendocrine tumors
Areas of interest include novel immuno-oncology combinations, targeted agents for molecular subsets, and treatment of metastatic or unresectable disease.
Precision Oncology and Advanced Solid Tumors
Across multiple tumor types, the investigator is involved in precision oncology programs for advanced solid tumors defined by molecular alterations such as MSI-H, dMMR, TMB-high, HER2 aberrations, and MTAP deficiency.
- Advanced solid tumors
- Biomarker-selected malignancies
- HER2-expressing cancers
- Mismatch repair–deficient tumors
- Tumor mutational burden–high disease
Therapeutic interests emphasize personalized systemic therapy and the evaluation of emerging agents in difficult-to-treat metastatic settings.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.